February 13, 2002
A few weeks ago, we advised you of a critical shortage of CYTOVENE-IV (ganciclovir sodium for injection) and asked that you consider alternative therapies or management strategies for your patients in order to avoid a complete out-of-stock situation.
Despite the implementation of a system to manage the available stock, demand exceeds our ability to supply Cytovene IV. Regretfully, we must inform you that will soon face a complete out-of-stock situation. While we expect to receive periodic shipments of Cytovene IV over the next few months, we may experience intermittent complete out-of-stock situations until the middle of the second quarter. We at Roche urge you to continue to explore alternative treatment therapies or management strategies for your patients.
Roche is fully committed the prevention and treatment of CMV disease and we are working as quickly as possible to resolve the current situation.
We regret any inconvenience this situation may cause and we appreciate your patience and support as we work to meet your needs. If you have any questions or need additional information, please call the Roche professional product information department at 1-800-526-6367, Monday - Friday 8 AM - 6 PM EST.
Please see a complete Cytovene and Valcyte product information enclosed.
James Thommes, M.D.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.